Trial · NCT05267600
Results by group65
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 65
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With CRoff at Week 36 | Efgartigimod PH20 SC | 8 | Participants | ||
| Number of Participants With CRoff at Week 36 | Placebo PH20 SC | 2 | Participants | ||
| Cumulative OCS Dose | Efgartigimod PH20 SC | 0.242 | Standard Deviation 0.138 | mg/kg/day | |
| Cumulative OCS Dose | Placebo PH20 SC | 0.289 | Standard Deviation 0.173 | mg/kg/day | |
| Number of Participants Who Achieve an IGA-BP Score of 0 While Off OCS Therapy for ≥8 Weeks at Week 36 | Efgartigimod PH20 SC | 9 | Participants | ||
| Number of Participants Who Achieve an IGA-BP Score of 0 While Off OCS Therapy for ≥8 Weeks at Week 36 | Placebo PH20 SC | 3 | Participants | ||
| Number of Participants With CDA Who Remained Free of Relapse Through Week 36 | Efgartigimod PH20 SC | 7 | Participants | ||
| Number of Participants With CDA Who Remained Free of Relapse Through Week 36 | Placebo PH20 SC | 8 | Participants | ||
| Number of Participants With CRmin at Week 36 | Efgartigimod PH20 SC | 8 | Participants | ||
| Number of Participants With CRmin at Week 36 | Placebo PH20 SC | 3 | Participants | ||
| Change From Baseline to Week 36 in the 24-Hour Average Itch NRS Score | Efgartigimod PH20 SC | -4.4 | Standard Deviation 3.35 | score on a scale | |
| Change From Baseline to Week 36 in the 24-Hour Average Itch NRS Score | Placebo PH20 SC | -2.4 | Standard Deviation 4.26 | score on a scale | |
| Changes From Baseline in the BPDAI Total Activity Score | Efgartigimod PH20 SC | -43.13 | Standard Deviation 19.633 | score on a scale | |
| Changes From Baseline in the BPDAI Total Activity Score | Placebo PH20 SC | -43.56 | Standard Deviation 32.584 | score on a scale | |
| Time to CDA | Efgartigimod PH20 SC | 16.0 | 95% Confidence Interval 10.0 to 17.0 | days | |
| Time to CDA | Placebo PH20 SC | 15.0 | 95% Confidence Interval 13.0 to 22.0 | days | |
| Time to CR | Efgartigimod PH20 SC | 134.0 | 95% Confidence Interval 85.0 to NA | days | |
| Time to CR | Placebo PH20 SC | 99.0 | 95% Confidence Interval 57.0 to 225.0 | days | |
| Time to CRmin | Efgartigimod PH20 SC | NA | 95% Confidence Interval 247.0 to NA | days | |
| Time to CRmin | Placebo PH20 SC | NA | 95% Confidence Interval NA to NA | days |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05267600/results